重大公告
Announcement on behalf of OBIGEN of the resignation of its institutional director
1.Date of occurrence of the change:2023/12/20 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): institutional director …
OBI announces termination of BCVax, OBI-866, and OBI-999
1.Date of occurrence of the event:2023/12/20 2.Company name:OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios: NA …
Announcement of resignation of the Chairperson
1.Date of the board of directors resolution or date of occurrence of the change:2023/12/20 2.Position (Please enter chairperson or president/general manager): Chairperson 3.Name of the …
OBI licensed the worldwide therapeutic rights of OBI-858 to OBIGEN
1.Date of occurrence of the event:2023/12/20 2.Counterparty to the contract or commitment: OBIGEN Pharma, Inc. 3.Relationship with the Company: OBIGEN is a subsidiary held 52% …
Announcement on behalf of subsidiary, OBIGEN, that the Company’s board appointed internal audit officer
1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information …